Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
← catalyst calendarNCT07688980 · readout in 968 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
92estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-30 | estimated | When the study began enrolling |
| Primary completion | 2029-04-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-06-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Interventions
- Combination product: Anifrolumab: SC formulation via AI
- Combination product: Anifrolumab: IV formulation
- Combination product: Anifrolumab: SC formulation via aPFS
Primary outcome
what the primary-completion date above is the date OFAnifrolumab serum concentrations through Week 4
measured Up to Week 4
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed